None listed
Conditions
Interventions
GLUCOSAMINE: (1) Oral Celecoxib- 200 mg in 3 divided doses for 24 weeks
(2) Glucosamine sulphate:2 gm, in 3 divided doses
Intervention1: SGPF'
C'
(AYURVEDIC): 2 CAPSULES THRICE DAILY AFTER MEALS,FOR 24 WEEKS
Intervention2: SGPF(AYURVEDIC): 2 CAPSULES THRICE DAILY AFTER MEALS, FOR 24 WEEKS
Control Intervention1: CELECOXIB &
Sponsors
CSIR
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex, 40 to 70 years of age. 2. Diagnosis of OA knees , based on typical history, clinical presentation, classical radiological findings and fulfilling the ACR classification criteria for OA knees 3 Presence of typical osteophytes on skiagram knee is mandatory 4. A minimum pain VAS score > 4 on walking in one or both knees during the 24 hours preceding recruitment. 5. Patient ambulant and requiring treatment with an anti- inflammatory drug and not receiving regular anti â?? inflammatory or analgesic drugs, or are not satisfied with drugs being taken and seek a change. 6. Willing to come for regular follow â?? up visits. 7. Written Informed Consent from the patient.
Exclusion criteria
Exclusion criteria: 1. Known history of hypersensitivity or intolerance to NSAIDs, aspirin, COX-2 inhibitors, NSAIDs and any other analgesic medicine. 2. Pregnant women, lactating women and women of child bearing potential not following adequate contraceptive measure. 3. Patients with known contraindication to Shunthi, Guduchi, Amalaki and Guggul formulation 4. Non degenerative joint diseases or other joint diseases which will interfere with the evaluation of OA. 5. Patients incapacitated or bound to wheel chair or bed and unable to carry out self care activities. 6. Treatment with intra-articular injection of corticosteroids into the knee within 3 months preceding the study. 7. Pre-existing or recent onset of demyelinating disorders or type I diabetes 8. Ongoing treatment with anticoagulants, hydantoin, lithium, steroids, methotrexate and colchicine. 9. Presence or history of active peptic ulcer in the preceding 6 months or bleeding ulcer at anytime in the past. 10. Evidence of severe renal, hepatic or hemopoietic disease or severe cardiac insufficiency as revealed by laboratory investigations or other tests. 11. Patient with congestive heart failure 12. All patients with Hypertension and IHD will be excluded. All patients with severe and/or uncontrolled Hypertension. (Appendix C) 13. Patients of IHD diagnosed as per conventional clinical and routine investigations in standard care practice will be excluded. Patients with ECG abnormalities suggestive of IHD will be excluded. 14. Clinically significant untreated hyperlipidemia in context of a Cardiovascular risk. The normal range of the site laboratory will be used to interpret the lipid values. The significance of Hyperlipidemia will be decided by the Investigator based on the associated risk factors. (Appendix D) 15. History of having received any investigational drug in preceding one month. 16. Ayurvedic formulation or any form of CAM (Complimentary Alternative Medicine) therapy in the preceding 2 months 17. Concurrent pain relieving medication such as antipyretics, analgesics, tranquilizers, hypnotics, excessive alcohol, NSAIDs, (Paracetamol & Tramadol are permitted in extreme pain, see below for details) which would interfere with pain perception. 18. Unwilling to come for regular follow-up for the entire duration of the study. 19. Non â?? co-operative attitude of the patient. 20. Any condition (especially in particular with reference to Cardiovascular safety profile) that, in the opinion of the investigator, does not justify the patientâ??s inclusion for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| i) PainVAS (Visual Analog Scale) on walking ii) WOMAC (Western Ontario Macmasters's Osteoarthritis Index for Knee-Indian CRD, Pune version of questionnaire) pain component (5 questions) iii) WOMAC difficulty (17 questions) Timepoint: Baseline, Week 2, Week 4, Week8, Week 12, Week 16, Week 20 and Week24. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Walk Time/ Speed of walking(seconds) (2) Patient Global assessment of disease (5 grades) (3)Physicianâ??s Global assessment of disease (5 grades) (4) Patientâ??s Global Assessment of Tolerability (5) Physicianâ??s Global Assessment of Tolerability (6) Physicianâ??s Global assessment of response to Therapy (7) Patientâ??s Global assessment of response to Therapy (8) Change in Status of knee arthritis as per patientâ??s perception (9) HAQ (Stanford Health assessment questionnaire, modified CRD Pune version) (10) WHO-QOL Bref (11) Ayurvedic variables (including Prakruti)of efficacy & safety (11)Cytokines :Reduction in blood levels of IL-1 , IL-6, TNF-α, MMP-1, 3, 13, HA and Urinay CTX-II (12)Digitised X-rays Timepoint: (1) Clinical variables at Baseline, Week 2, Week 4, Week8, Week 12, Week 16, Week 20 and Week24. (2) Laboratory and Digitised X-rays at baseline and week 24 (3) Ayurvedic varaibles at all clinical endpoints | — |
Countries
India
Contacts
Public ContactDR ARVIND CHOPRA
Outcome results
None listed